Finoriq research workspace
Nuvation Bio Inc. (NUVB) SEC Filings & Filing Highlights
Review SEC filings, SEC-derived company events, filing highlights, source excerpts, and material disclosure activity for Nuvation Bio Inc. (NUVB).
Company Snapshot
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
- Company
- Nuvation Bio Inc. (NUVB)
- Ticker
- NUVB
- Market Cap
- $2.2B
- Latest Price
- $6.29
- Industry
- Biotech & Pharma
Nuvation Bio Inc. (NUVB) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Nuvation Bio Inc. (NUVB).
| Event | Form | Date |
|---|---|---|
| Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 MillionNuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million | 8-K8.01 | 2026-07-06 |
| Debt or FinancingDebt or Financing | 8-K2.03 | 2026-07-06 |
| Nuvation Bio Announces Proposed Convertible Senior Notes OfferingNuvation Bio Announces Proposed Convertible Senior Notes Offering | 8-K8.01 | 2026-06-30 |
| Debt or FinancingDebt or Financing | 8-K2.03 | 2026-06-30 |
| Nuvation Bio Inc.: Agreement terminationIn connection with the Offering and the issuance of Notes thereunder, on June 30, 2026, the Company completed a voluntary prepayment of all... | 8-K1.02 | 2026-06-30 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.